Itacitinib + Prednisone + Methylprednisolone
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
GVHD,Acute
Conditions
GVHD,Acute
Trial Timeline
Jun 18, 2020 → Oct 10, 2020
NCT ID
NCT04220632About Itacitinib + Prednisone + Methylprednisolone
Itacitinib + Prednisone + Methylprednisolone is a phase 1/2 stage product being developed by Innovent Biologics for GVHD,Acute. The current trial status is terminated. This product is registered under clinical trial identifier NCT04220632. Target conditions include GVHD,Acute.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04220632 | Phase 1/2 | Terminated |
Competing Products
19 competing products in GVHD,Acute